ClinicalTrials.gg
Active, not recruitingNCT03155997monarchEUpdated Apr 24, 2026Results posted

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

A Phase 3 interventional study of Abemaciclib and Standard Adjuvant Endocrine Therapy in Breast Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 619 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,637
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
Largest of 55
5,637 · median 120
Started
2017
with 2 others
Phase 3
11 of 55
2 open now
Primary completion
2020-03
later than 4 of 33 live
Registered
13th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one has the largest enrollment, is one of 3 that started in 2017, is one of 11 in phase 3, reaches primary completion later than 4 of the 33 other live ones, and was the 13th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • early stage breast cancer
  • cyclin-dependent kinase (CDK)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women (regardless of menopausal status) or men ≥18 years of age (or per local regulations).
  • The participant has confirmed HR+, -, early stage resected invasive breast cancer without evidence of distant .
  • The participant must have undergone definitive surgery of the primary breast tumor.
  • The participant must have tumor tissue from breast (preferred) or lymph node for exploratory biomarker analysis available prior to randomization.
  • Pathologic lymph node involvement and at least one of the following indicating a higher risk of recurrence:

    • 4 or more positive axillary lymph nodes
    • Tumor size of at least 5 centimeters
    • Grade 3 defined as at least 8 points on the Bloom Richardson grading system
    • Ki-67 index by central analysis of ≥20% on untreated breast tissue
  • The participant must be randomized within 16 months from the time of definitive breast cancer surgery.
  • The participant may receive up to 12 weeks of endocrine therapy until randomization following the last non-endocrine therapy (surgery, chemotherapy, or radiation) whichever is last.
  • Participants must have recovered (grade ≤1) from the acute effects of chemotherapy and radiotherapy and from surgical side effects following definitive breast surgery.
  • Women of must have a negative blood pregnancy test and agree to use highly effective methods.
  • The participant has a (ECOG) performance status ≤1.
  • The participant has adequate organ function.
  • The participant is able to swallow oral medications.

Exclusion criteria

Exclusion Criteria:

  • disease (including contralateral axillary lymph nodes) or node-negative disease.
  • Participants with inflammatory breast cancer.
  • Participants with a history of previous breast cancer, with the exception of ipsilateral ductal carcinoma in situ (DCIS) treated by locoregional therapy alone ≥5 years ago. Participants with a history of contralateral DCIS treated by local regional therapy at any time may be eligible. Participants with a history of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission with no therapy for a minimum of 5 years from the date of randomization are excluded.
  • Females who are pregnant or lactating.
  • The participant has previously received treatment with any CDK4 and CDK6 inhibitor.
  • The participant is receiving concurrent exogenous reproductive hormone therapy (for example, pills, hormone replacement therapy, or megestrol acetate).
  • The participant has previously received endocrine therapy for breast cancer prevention (tamoxifen or aromatase inhibitors) or raloxifene.
  • The participant has serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.
  • The participant has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin or sudden cardiac arrest. Any participant with a history of venous thromboembolism (VTE).
  • The participant has active systemic infections or viral load.
  • The participant has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,637 participants (actual)

Study arms

  • Experimental
    150 mg Abemaciclib + Endocrine Therapy

    Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.

    Drug: Abemaciclib · Drug: Standard Adjuvant Endocrine Therapy

  • Other
    Endocrine Therapy

    Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.

    Drug: Standard Adjuvant Endocrine Therapy

Interventions

  • Administered orally.

    Also known as: LY2835219

  • DrugStandard Adjuvant Endocrine Therapy

    Administered according to label instructions.

06

What researchers measure

Primary outcomes

  1. Invasive Disease Free Survival (IDFS)

    IDFS, as defined by the STEEP System, was measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause.

    Time frame: Baseline to Recurrence or Death from Any Cause (Up to 32 Months)

Secondary outcomes

  1. IDFS for Participants With Ki-67 Index ≥20%

    Outcome data will be provided after the study is completed.

    Time frame: Baseline to Recurrence or Death from Any Cause (Approximately 10 Years)

  2. Distant Relapse-Free Survival (DRFS)

    Distant relapse-free survival is defined as the time from randomization to distant recurrence or death from any cause, whichever occurs first.

    Time frame: Baseline to Distant Recurrence or Death from Any Cause (Up to 32 Months)

  3. Overall Survival (OS)

    Outcome data will be provided after the study is completed.

    Time frame: Baseline to Death from Any Cause (Approximately 10 Years)

  4. Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib

    Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib

    Time frame: Day 1 (2 hours post-dose), Days 30, 60, 90 post-dose

  5. Change From Baseline on the Functional Assessment of Cancer Therapy - Breast (FACT-B)

    Outcome data will be provided after the study is completed.

    Time frame: Baseline, Follow Up (Approximately 3 Years)

  6. Change From Baseline on the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)

    Outcome data will be provided after the study is completed.

    Time frame: Baseline, Follow Up (Approximately 3 Years)]

  7. Change From Baseline on the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)

    Outcome data will be provided after the study is completed.

    Time frame: Baseline, Follow Up (Approximately 3 Years)]

  8. Change From Baseline on the EuroQol Five-Dimension Five-Level Questionnaire (EQ-5D-5L)

    Outcome data will be provided after the study is completed.

    Time frame: Baseline, Follow Up (Approximately 3 Years)]

07

Results

Posted Apr 9, 2021

Participant flow

Completers included participants who had recurrence disease, death due to any cause, and participants off treatment but on study follow-up.

Participant flow — Overall Study
Milestone150 mg Abemaciclib + Endocrine TherapyEndocrine Therapy
Started28082829
Received at least one dose of study drug27912800
Completed650607
Not completed21582222
Withdrew: Withdrawal by subject119134
Withdrew: Lost to follow-up1213
Withdrew: Missing disposition data01
Withdrew: On study treatment20272074

Outcome measures

PrimaryInvasive Disease Free Survival (IDFS)

IDFS, as defined by the STEEP System, was measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause.

Time frame:
Baseline to Recurrence or Death from Any Cause (Up to 32 Months)
Reported as:
Median · Months
Invasive Disease Free Survival (IDFS)
Months150 mg Abemaciclib + Endocrine TherapyEndocrine Therapy
Invasive Disease Free Survival (IDFS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • 150 mg Abemaciclib + Endocrine Therapy vs Endocrine Therapy · Log Rank · p = 0.00957 · Hazard ratio (hr): 0.747 · 95% CI 0.598 to 0.932Stratified by IWRS Geographical Region, IWRS Prior Treatment, IWRS Menopausal Status
SecondaryIDFS for Participants With Ki-67 Index ≥20%

Outcome data will be provided after the study is completed.

Time frame:
Baseline to Recurrence or Death from Any Cause (Approximately 10 Years)

Results for this outcome have not been posted.

SecondaryDistant Relapse-Free Survival (DRFS)

Distant relapse-free survival is defined as the time from randomization to distant recurrence or death from any cause, whichever occurs first.

Time frame:
Baseline to Distant Recurrence or Death from Any Cause (Up to 32 Months)
Reported as:
Median · Months
Distant Relapse-Free Survival (DRFS)
Months150 mg Abemaciclib + Endocrine TherapyEndocrine Therapy
Distant Relapse-Free Survival (DRFS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • 150 mg Abemaciclib + Endocrine Therapy vs Endocrine Therapy · Hazard ratio (hr): 0.717 · 95% CI 0.559 to 0.920Stratified by IWRS Geographical Region, IWRS Prior Treatment, IWRS Menopausal Status
SecondaryOverall Survival (OS)

Outcome data will be provided after the study is completed.

Time frame:
Baseline to Death from Any Cause (Approximately 10 Years)

Results for this outcome have not been posted.

SecondaryPharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib

Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib

Time frame:
Day 1 (2 hours post-dose), Days 30, 60, 90 post-dose
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib
Nanograms per milliliter (ng/mL)150 mg Abemaciclib + Endocrine Therapy
Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib143 ± 110
SecondaryChange From Baseline on the Functional Assessment of Cancer Therapy - Breast (FACT-B)

Outcome data will be provided after the study is completed.

Time frame:
Baseline, Follow Up (Approximately 3 Years)

Results for this outcome have not been posted.

SecondaryChange From Baseline on the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)

Outcome data will be provided after the study is completed.

Time frame:
Baseline, Follow Up (Approximately 3 Years)]

Results for this outcome have not been posted.

SecondaryChange From Baseline on the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)

Outcome data will be provided after the study is completed.

Time frame:
Baseline, Follow Up (Approximately 3 Years)]

Results for this outcome have not been posted.

SecondaryChange From Baseline on the EuroQol Five-Dimension Five-Level Questionnaire (EQ-5D-5L)

Outcome data will be provided after the study is completed.

Time frame:
Baseline, Follow Up (Approximately 3 Years)]

Results for this outcome have not been posted.

Adverse events

Collected over Baseline to 32 Months. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
150 mg Abemaciclib + Endocrine Therapy38/2,791 (1.4%)344/2,791 (12.3%)2,723/2,791 (97.6%)
Endocrine Therapy36/2,800 (1.3%)202/2,800 (7.2%)2,318/2,800 (82.8%)
Most frequent serious events
Showing 10 of 294
Most frequent serious events
Event150 mg Abemaciclib + Endocrine TherapyEndocrine Therapy
PneumoniaInfections and infestations23/279114/2800
Pulmonary embolismRespiratory, thoracic and mediastinal disorders16/27913/2800
Deep vein thrombosisVascular disorders16/27913/2800
DiarrhoeaGastrointestinal disorders15/27910/2800
Urinary tract infectionInfections and infestations12/27914/2800
CellulitisInfections and infestations11/27919/2800
CholecystitisHepatobiliary disorders10/27912/2800
AnaemiaBlood and lymphatic system disorders8/27912/2800
PyrexiaGeneral disorders7/27910/2800
InfluenzaInfections and infestations7/27913/2800
Most frequent other events
Showing 10 of 130
Most frequent other events
Event150 mg Abemaciclib + Endocrine TherapyEndocrine Therapy
DiarrhoeaGastrointestinal disorders2294/2791199/2800
NeutropeniaBlood and lymphatic system disorders1246/2791140/2800
FatigueGeneral disorders1073/2791433/2800
LeukopeniaBlood and lymphatic system disorders1026/2791171/2800
Abdominal painGastrointestinal disorders945/2791226/2800
ArthralgiaMusculoskeletal and connective tissue disorders571/2791876/2800
NauseaGastrointestinal disorders779/2791222/2800
AnaemiaBlood and lymphatic system disorders634/279188/2800
Hot flushVascular disorders393/2791587/2800
HeadacheNervous system disorders482/2791359/2800

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)150 mg Abemaciclib + Endocrine TherapyEndocrine TherapyTotal
Mean52.20 ± 11.2652.10 ± 11.2052.10 ± 11.23
Sex: Female, Male
Sex: Female, Male(Participants)150 mg Abemaciclib + Endocrine TherapyEndocrine TherapyTotal
Female278728145601
Male211536
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)150 mg Abemaciclib + Endocrine TherapyEndocrine TherapyTotal
Hispanic or Latino355378733
Not Hispanic or Latino173417383472
Unknown or Not Reported7197131432
Race (NIH/OMB)
Race (NIH/OMB)(Participants)150 mg Abemaciclib + Endocrine TherapyEndocrine TherapyTotal
American Indian or Alaska Native6458122
Asian6756691344
Native Hawaiian or Other Pacific Islander347
Black or African American5753110
White194719783925
More than one race222547
Unknown or Not Reported404282
Region of Enrollment
Region of Enrollment(Participants)150 mg Abemaciclib + Endocrine TherapyEndocrine TherapyTotal
Argentina7768145
Australia108109217
Austria222042
Belgium6551116
Brazil144153297
Canada281644
China187170357
Czechia151227
Denmark5458112
Finland454994
France86101187
Germany148152300
Greece7464138
Hong Kong81220
Hungary242852
India5953112
Israel393877
Italy7259131
Japan181196377
Mexico104121225
Netherlands51419
New Zealand212243
Poland6560125
Portugal211637
Puerto Rico134
Romania5360113
Russia6673139
Saudi Arabia5914
Singapore112132
South Africa369
South Korea122123245
Spain144148292
Sweden7512
Taiwan6460124
Turkey125110235
Ukraine5451105
United Kingdom99100199
United States402418820
08

Study locations

619 sites

Showing the first 100 of 619 sites across 38 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Johnston S, Martin M, O'Shaughnessy J, Hegg R, Tolaney SM, Guarneri V, Del Mastro L, Campone M, Sohn J, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, Munoz M, San Antonio B, Shahir A, Rastogi P, Harbeck N. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026 Feb;37(2):155-165. doi: 10.1016/j.annonc.2025.10.005. Epub 2025 Oct 17. PubMed 41110697 ↗
  • Zhang Q, Shen K, Song CG, Ouyang Q, Liu Z, Liu Q, Feng J, Chiu JWY, Tang J, Jiang Z, Tseng LM, Wang X, Yang L, Qian C, Shao Z. Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study. Ther Adv Med Oncol. 2024 Oct 23;16:17588359241286775. doi: 10.1177/17588359241286775. eCollection 2024. PubMed 39463748 ↗
  • Johnston SRD, Rugo HS, Tolaney SM, Munoz Fernandez M, Wei R, Martin M. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study. Future Oncol. 2024;20(28):2037-2048. doi: 10.1080/14796694.2024.2362095. Epub 2024 Jul 18. PubMed 39023253 ↗
  • Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, Andre V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol. 2024 Mar 20;42(9):987-993. doi: 10.1200/JCO.23.01994. Epub 2024 Jan 9. PubMed 38194616 ↗
  • Ganfornina Andrades A, Fenix Caballero S, Salguero Olid A, Alegre Del-Rey Emilio J. Abemaciclib as adjuvant treatment for high-risk early breast cancer. Farm Hosp. 2024 Mar-Apr;48(2):75-78. doi: 10.1016/j.farma.2023.08.006. Epub 2023 Sep 19. English, Spanish. PubMed 37735004 ↗
  • Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, Andre V, Harbeck N, Martin M; monarchE Committee Members. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. PubMed 36493792 ↗
  • Toi M, Boyle F, Im YH, Reinisch M, Molthrop D, Jiang Z, Wei R, Sapunar F, Grimes BR, Nabinger SC, Johnston SRD. Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1. Oncologist. 2023 Jan 18;28(1):e77-e81. doi: 10.1093/oncolo/oyac234. PubMed 36342342 ↗
  • Martin M, Hegg R, Kim SB, Schenker M, Grecea D, Garcia-Saenz JA, Papazisis K, Ouyang Q, Lacko A, Oksuzoglu B, Reeves J, Okera M, Testa L, Shimizu C, Denduluri N, Adamchuk H, Dakhil S, Wei R, Forrester T, Fernandez MM, Zimmermann A, Headley D, Johnston SRD. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial. JAMA Oncol. 2022 Aug 1;8(8):1190-1194. doi: 10.1001/jamaoncol.2022.1488. PubMed 35653145 ↗
  • Perachino M, Poggio F, Arecco L, Blondeaux E, Spinaci S, Marrocco C, Levaggi A, Lambertini M. Update on Pregnancy Following Breast Cancer Diagnosis and Treatment. Cancer J. 2022 May-Jun 01;28(3):176-182. doi: 10.1097/PPO.0000000000000599. PubMed 35594464 ↗
  • Polewski MD, Nielsen GB, Gu Y, Weaver AT, Gegg G, Tabuena-Frolli S, Cajaiba M, Hanks D, Method M, Press MF, Gottstein C, Gruver AM. A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone. Appl Immunohistochem Mol Morphol. 2022 Apr 1;30(4):237-245. doi: 10.1097/PAI.0000000000001009. PubMed 35384873 ↗
  • Rugo HS, O'Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, Gumus M, Yamashita T, Im YH, Rastogi P, Zagouri F, Song C, Campone M, San Antonio B, Shahir A, Hulstijn M, Brown J, Zimmermann A, Wei R, Johnston SRD, Reinisch M, Tolaney SM; monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022 Jun;33(6):616-627. doi: 10.1016/j.annonc.2022.03.006. Epub 2022 Mar 23. PubMed 35337972 ↗
  • Royce M, Osgood C, Mulkey F, Bloomquist E, Pierce WF, Roy A, Kalavar S, Ghosh S, Philip R, Rizvi F, Mixter BD, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. J Clin Oncol. 2022 Apr 10;40(11):1155-1162. doi: 10.1200/JCO.21.02742. Epub 2022 Jan 27. PubMed 35084948 ↗
  • Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortes J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20. PubMed 32954927 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Mar 2020, 32 months.

Results were first posted in Apr 2021, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 32 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2017
First posted
May 16, 2017
StartActual
Jul 12, 2017
Primary completionActual
Mar 16, 2020
CompletionEst.
May 2029
Results first posted
Apr 9, 2021
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03155997
Collaborators
NSABP Foundation Inc
Responsible party
Sponsor
First posted
May 16, 2017
Start date
Jul 12, 2017
Primary completion
Mar 16, 2020
Completion
May 2029 (estimated)
Results posted
Apr 9, 2021
Last update
Apr 24, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion